This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Macquarie Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
In a report released yesterday, Tony Ren from Macquarie maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$40.00. The company’s shares closed yesterday at $4.20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ren covers the Healthcare sector, focusing on stocks such as Chugai Pharmaceutical Co, CSPC Pharmaceutical Group, and Olympus. According to TipRanks, Ren has an average return of 15.6% and a 59.26% success rate on recommended stocks.
In addition to Macquarie, Wuxi Biologics (Cayman) also received a Buy from Citi’s John Yung in a report issued yesterday. However, on the same day, Goldman Sachs maintained a Hold rating on Wuxi Biologics (Cayman) (Other OTC: WXIBF).
WXIBF market cap is currently $15.52B and has a P/E ratio of 26.90.
Read More on WXIBF:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
